InvestorsHub Logo
Followers 21
Posts 1025
Boards Moderated 0
Alias Born 04/07/2008

Re: None

Thursday, 06/07/2018 2:16:29 AM

Thursday, June 07, 2018 2:16:29 AM

Post# of 1675
In case anyone missed it.

Oramed started their 240 participant HbA1c 12 week study in T2DM, last month. It was due to begin in 1Q 2018, so a little delayed but not by much.

https://clinicaltrials.gov/ct2/show/NCT03467932?term=oramed&rank=4

This study will be critical for FDA approval to progress to Phase III

Study expected to be about 12-18 months.

The study data so far in terms of ORMD-0801 on HbA1c is compelling so this study should be more of a confirmatory formality of prior results, (see company presentation slide 27).
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent ORMP News